X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
[ sdv.can ] life sciences [q-bio]/cancer (7) 7
cancer (7) 7
life sciences (7) 7
humans (4) 4
nivolumab (4) 4
oncology (4) 4
docetaxel (3) 3
immunology (3) 3
immunotherapy (3) 3
index medicus (3) 3
lung cancer (3) 3
middle aged (3) 3
pd-1 blockade (3) 3
[ sdv.bc ] life sciences [q-bio]/cellular biology (2) 2
aged (2) 2
aged, 80 and over (2) 2
anti-bacterial agents - therapeutic use (2) 2
antibiotics (2) 2
antibodies, monoclonal - therapeutic use (2) 2
bevacizumab (2) 2
cell (2) 2
cell biology (2) 2
cell lung-cancer (2) 2
cellular biology (2) 2
chemotherapy (2) 2
clinical research paper (2) 2
cyclophosphamide (2) 2
disease-free survival (2) 2
expression (2) 2
female (2) 2
glioblastoma (2) 2
lymphocytes (2) 2
male (2) 2
microbiota (2) 2
newly-diagnosed glioblastoma (2) 2
ngs (2) 2
open-label (2) 2
original research (2) 2
retrospective studies (2) 2
targeted therapy (2) 2
treatment outcome (2) 2
+ (1) 1
1st-line treatment (1) 1
abundance (1) 1
adenocarcinoma (1) 1
adult (1) 1
adénocarcinome (1) 1
age factors (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
animals (1) 1
anti-bacterial agents - adverse effects (1) 1
anti-pd-l1 antibody (1) 1
antibodies, monoclonal - adverse effects (1) 1
anticancer properties (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antitumor activity (1) 1
antitumor immunity (1) 1
apoptosis (1) 1
bacteria (1) 1
bevacizumab - therapeutic use (1) 1
biomarkers (1) 1
biomarkers, pharmacological - blood (1) 1
brain neoplasms - blood (1) 1
brain neoplasms - mortality (1) 1
brain neoplasms - pathology (1) 1
brain neoplasms - therapy (1) 1
brain-tumors (1) 1
cancer bronchique (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
care and treatment (1) 1
ccr9 protein (1) 1
cd4 antigen (1) 1
cd4 antigens - immunology (1) 1
cd8 (1) 1
cd8 t cells (1) 1
cd8+ t cells (1) 1
cell receptors (1) 1
chemoradiotherapy (1) 1
chi-square distribution (1) 1
clinical research (1) 1
colony-stimulating factor (1) 1
cxcr3 protein (1) 1
dietary supplements (1) 1
egfr mutations (1) 1
endothelial growth-factor (1) 1
epidermal growth factor (1) 1
epithelial tumors (1) 1
eye diseases (1) 1
factor receptor mutations (1) 1
fecal microbiota transplantation (1) 1
feces (1) 1
feces - microbiology (1) 1
first-line chemotherapy (1) 1
flora (1) 1
follow-up studies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 2024 - 2024
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e20523 - e20523
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 3026 - 3026
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 43, pp. 70948 - 70958
Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the... 
Glioblastoma | Bevacizumab | Prognosistic factor | COLONY-STIMULATING FACTOR | NEWLY-DIAGNOSED GLIOBLASTOMA | RECURRENT GLIOBLASTOMA | prognosistic factor | BRAIN-TUMORS | CELL BIOLOGY | MALIGNANT GLIOMA | PHASE-II TRIAL | glioblastoma | SINGLE-AGENT BEVACIZUMAB | PRETREATMENT NEUTROPHIL | bevacizumab | TO-LYMPHOCYTE RATIO | ENDOTHELIAL GROWTH-FACTOR | Bevacizumab - therapeutic use | Prognosis | Age Factors | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | Male | Gene Expression Profiling | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Neoplasm Recurrence, Local - mortality | Chemoradiotherapy | Neoplasm Recurrence, Local - pathology | Karnofsky Performance Status | Brain Neoplasms - blood | Angiogenesis Inhibitors - therapeutic use | Female | Leukocyte Count | Retrospective Studies | Brain Neoplasms - mortality | Neoplasm Recurrence, Local - blood | Granulocyte Colony-Stimulating Factor - metabolism | Neoplasm Recurrence, Local - therapy | Glioblastoma - blood | Neutrophils | Treatment Outcome | Biomarkers, Pharmacological - blood | Randomized Controlled Trials as Topic | Glioblastoma - therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Glioblastoma - pathology | Neoadjuvant Therapy - methods | Brain Neoplasms - therapy | Glioblastoma - mortality | Life Sciences | Cellular Biology | Cancer
Journal Article
OncoImmunology, ISSN 2162-4011, 06/2017, Volume 6, Issue 6, p. e1321186
Background: Interest is growing on immune cells involvement in central nervous system tumors such as glioblastoma. Even if a few reports highlighted that... 
Angiogenesis | glioblastoma | CD8 | immune infiltrate | + | Th17 T cells | T cells | SURVIVAL | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | GLIOMA | IMMUNOLOGY | CANCER | TEMOZOLOMIDE | ONCOLOGY | CD8(+) T cells | REGULATORY T-CELLS | EXPRESSION | LYMPHOCYTES | Life Sciences | Cancer
Journal Article
Cancers, ISSN 2072-6694, 02/2019, Volume 11, Issue 2, p. 201
Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit... 
Biomarkers | Immunotherapy | Lung cancer | biomarkers | PD-1 BLOCKADE | MISMATCH REPAIR | OPEN-LABEL | DOCETAXEL | CHEMOTHERAPY | ONCOLOGY | immunotherapy | NIVOLUMAB | TUMOR MUTATIONAL BURDEN | CELL | EXPRESSION
Journal Article
OncoImmunology, ISSN 2162-4011, 09/2017, Volume 6, Issue 9, p. e1339856
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard... 
nivolumab | Non-small-cell lung cancer | First-line chemotherapy | PD-1 BLOCKADE | SENSITIVITY | INNATE | IMMUNOLOGY | DOCETAXEL | GEMCITABINE | ANTI-PD-L1 ANTIBODY | THERAPY | NAIVE PATIENTS | ONCOLOGY | IMMUNE CHECKPOINT BLOCKADE | IMMUNOTHERAPY | Life Sciences | Cancer
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 11/2018, Volume 2018, Issue 506, pp. 46 - 51
Le carcinome bronchique est un problème majeur de santé publique avec 1,8 million de nouveaux cas par an et représente la première cause de mortalité par... 
inhibiteur de tyrosine kinase | lung cancer | targeted therapy | adénocarcinome | thérapie ciblée | adenocarcinoma | cancer bronchique | NGS | tyrosine kinase inhibitor
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.